Phase 1/1B Open-Label, Dose-Escalation Study of APVO436 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2019
Price : $35 *
At a glance
- Drugs APVO-436 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Aptevo Therapeutics
- 03 Oct 2019 Results presented in an Aptevo Therapeutics media release.
- 03 Oct 2019 According to an Aptevo Therapeutics media release, dosing of three patients in cohort 4 is completing in the trial, with dosing in cohort 5 scheduled to begin shortly. The company intends to advance this study to capture additional data at higher dose levels. The data from the higher dose cohorts is expected over the next several months.
- 09 Sep 2019 Planned End Date changed from 15 Nov 2019 to 15 Dec 2021.